Harga ArkARK

Bitcoin spot ETFs had a total net inflow of $755 million on January 15, the first net inflow after net outflows in the past four days. Fidelity ETF FBTC had a net inflow of $463 million per day, and Ark Invest and 21Shares' ETF ARKB had a net inflow of $139 million per day.

Bitcoin’s technological ecosystem continues to evolve, enhancing its scalability, privacy, and utility. “Layer 2” (L2) innovations like the Lightning Network enables near-instant transactions at negligible cost. Newer L2 technologies like Ark and Fedimints will continue to mature, pushing forward bitcoin’s viability as a medium of exchange. Upcoming advancements, such as privacy-enhancing features like Silent Payments and improved self-custody solutions will make bitcoin even more secure and accessible. Additionally, bitcoin-backed lending protocols are poised to unlock liquidity without requiring holders to give up custody of their assets. These developments will reinforce bitcoin’s appeal as 

The cryptocurrency market witnessed contrasting movements in the Ethereum $ETH and Bitcoin $BTC spot ETFs on January 14, 2025. While Spot Ethereum ETFs recorded significant inflows, Spot Bitcoin ETFs experienced notable outflows. Ethereum Spot ETF Surge and Positive Inflows The Spot Ethereum ETF market saw a net inflow of $1.1527 million on January 14, reflecting growing investor confidence. This inflow contributed to the cumulative total net inflow, which now stands at $2.414 billion. The total net asset value of Ethereum spot ETFs has reached $11.398 billion, accounting for 2.94% of Ethereum’s market cap. Key highlights of the day include the Bitwise Ethereum ETF (ETHW), which reported a daily net inflow of $1.15 million, bringing its cumulative net inflow to $343.12 million. ETHW's market price stood at $23.14, with a trading volume of 112,140 shares and $2.59 million in value traded. The ETF’s slight premium of 0.38% indicates steady investor demand. At the time of writing, Ethereum was trading at $3,226.92, showing an intraday surge of 1.83%. With a market cap of $388.83 billion and a 24-hour trading volume of $23.11 billion, Ethereum continues to attract attention as Spot Ether ETFs expand their reach. Bitcoin Spot ETF News: Outflows Dominate Contrary to Ethereum, Spot Bitcoin ETFs faced significant outflows totaling $209.82 million. Leading the declines were GBTC (-$89.01M), FBTC (-$113.6M), and ARKB (-$92.36M). Despite this, minor inflows from Ark & Invest ARKB ($2.89M) and VanEck HODL ($5.46M) partially offset the losses. The total net asset value of Bitcoin spot ETFs currently sits at $108.98 billion, representing 5.70% of Bitcoin’s market cap. Bitcoin was trading at $96,933.26, with a 1.91% intraday increase and a market cap of $1.92 trillion. However, the sustained outflows highlight market caution amid fluctuating prices. Future Outlook With Ethereum ETF inflows and an increasing Spot Ethereum ETF list, Ethereum’s ETF market appears poised for growth, bolstered by investor optimism and potential adoption by institutional players like BlackRock’s Ethereum ETF. Conversely, Bitcoin’s ETF outflows suggest short-term consolidation, but long-term prospects remain robust as demand for Spot Bitcoin ETFs stabilizes.

By 2025, Bitcoin (BTC) will reach $250,000, and Ethereum (ETH) will reach $12,000." This is a prediction I just made up, it may come true or it may not. In fact, most predictions are like this. Although some predictions are based on data, such as VanEck's well-founded predictions, Cathie Wood (CEO of ARK Invest) is known for making bold predictions with amazing numbers. She predicts that BTC will reach $500,000 by 2026 and $1 million by 2030. As for Michael Saylor, he predicts that the price of BTC will reach $13 million by 2045. $BTC $ETH $BGB

There's a lot to like about this business, but it's still a risky bet. Ginkgo Bioworks (DNA -1.52%) has a lot going for it. It's a favorite of Cathie Wood's Ark Innovation ETF, it's a popular collaborator in the biopharma sector, and its positioning at the intersection of biotechnology, artificial intelligence (AI), and laboratory robotics means that it's exposed to a lot of exciting and value-enhancing developments. But does that make it a buy, or just another stock getting hyped by the tech-hungry investors of the current bull market? Here's what you need to know.Why this company is probably going places When biopharma businesses need to manufacture a large quantity of a biological reagent or product of some kind, they often choose to outsource it. But in order to outsource the process properly, they have to define the steps the contractors need to do to fulfill the specification. And in the context of bioengineering tasks for biomanufacturing purposes, that can be a tall order as the processes and technologies used for laboratory-scale work tend to be very different from the processes used for mass production. Ginkgo Bioworks aims to address that issue while also providing sought-after biomanufacturing services. In a nutshell, the company's idea is to be a biofoundry, which means that it'll take designs for customized biological outputs like proteins or cells, and then implement a tailored manufacturing process that results in customers receiving those outputs at (ideally) industrial scale. By relying as heavily as possible on automation of the cognitive and manual work involved, it hopes to be more efficient than what customers could manage on their own. What each customer needs from Gingko Bioworks is somewhat unique and usually more complicated than a basic pharmaceutical manufacturing routine. But there is evidence that capable players are finding real value in working with Ginkgo: Novo Nordisk, Pfizer, and many other biopharmas and agribusinesses are already running programs on its platform.Accessibility Menu ▲ S&P 500 +172% | ▲ Stock Advisor +891% The Motley Fool Top 10 Stocks to Buy Now › Free Article Is Ginkgo Bioworks Stock a Buy? By Alex Carchidi – Mar 15, 2024 at 5:07PM Key Points Ginkgo Bioworks is trying to make good on its promises of scaling up. It's adding plenty of new programs, but its revenue is lagging. Likewise, the company's ambitions of high efficiency have yet to be realized. Buy Alert: Our 10 best stocks to buy right now (see the list) There's a lot to like about this business, but it's still a risky bet. Ginkgo Bioworks (DNA -1.52%) has a lot going for it. It's a favorite of Cathie Wood's Ark Innovation ETF, it's a popular collaborator in the biopharma sector, and its positioning at the intersection of biotechnology, artificial intelligence (AI), and laboratory robotics means that it's exposed to a lot of exciting and value-enhancing developments. But does that make it a buy, or just another stock getting hyped by the tech-hungry investors of the current bull market? Here's what you need to know. Expand NYSE: DNA Ginkgo Bioworks Today's Change (-1.52%) -US$0.17 Current Price US$11.03 Why this company is probably going places When biopharma businesses need to manufacture a large quantity of a biological reagent or product of some kind, they often choose to outsource it. But in order to outsource the process properly, they have to define the steps the contractors need to do to fulfill the specification. And in the context of bioengineering tasks for biomanufacturing purposes, that can be a tall order as the processes and technologies used for laboratory-scale work tend to be very different from the processes used for mass production. Ginkgo Bioworks aims to address that issue while also providing sought-after biomanufacturing services. In a nutshell, the company's idea is to be a biofoundry, which means that it'll take designs for customized biological outputs like proteins or cells, and then implement a tailored manufacturing process that results in customers receiving those outputs at (ideally) industrial scale. By relying as heavily as possible on automation of the cognitive and manual work involved, it hopes to be more efficient than what customers could manage on their own. What each customer needs from Gingko Bioworks is somewhat unique and usually more complicated than a basic pharmaceutical manufacturing routine. But there is evidence that capable players are finding real value in working with Ginkgo: Novo Nordisk, Pfizer, and many other biopharmas and agribusinesses are already running programs on its platform. Motley Fool Returns Motley Fool Stock Advisor Market-beating stocks from our flagship service. Stock Advisor Returns 891% S&P 500 Returns 172% Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 01/08/2025. Discounted offers are only available to new members. Stock Advisor list price is $199 per year. Join Stock Advisor In fact, it added 78 new programs in 2023 to reach a total of 162, and it was running more than twice as many programs for customers in pharma than it was two years prior. That led to the segment bringing in revenue of $44 million last year out of a top line of more than $251 million. Ginkgo isn't yet profitable on an operational basis. But as its biofoundry gains more customers, more programs, and more throughput, it could be able to drive its costs of servicing each program downward. Then it could undercut the other biological manufacturing businesses while potentially returning capital to its investors as well. And that'd make it a smart purchase today -- if it happensThe main argument for not buying Ginkgo stock is the company's difficulty in maintaining a steadily growing base of revenue. Furthermore, its expenditures are soaring in absolute terms, as well as when expressed as a proportion of revenue. Take a look at this chart